Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK plus ) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial Meeting Abstract
| Authors: | Solomon, B. J.; Drilon, A.; Lin, J. J.; Bazhenova, L.; Goto, K.; De Langen, J.; Kim, D. W.; Wolf, J.; Springfeld, C.; Popat, S.; Lim, D. W. T.; Baik, C. S.; Hervieu, A.; Garcia, V. M.; Yang, N.; Thamake, S.; Ades, F.; Trone, D.; Besse, B. |
| Abstract Title: | Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK plus ) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial |
| Meeting Title: | ESMO Congress 2023 |
| Journal Title: | Annals of Oncology |
| Volume: | 34 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2023 Oct 20-24 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-10-01 |
| Start Page: | S787 |
| End Page: | S788 |
| Language: | English |
| ACCESSION: | WOS:001087480202049 |
| PROVIDER: | wos |
| DOI: | 10.1016/j.annonc.2023.09.2405 |
| Notes: | Meeting Abstract: 1372P -- Source: Wos |
